Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Seres Therapeutics history
Seres Therapeutics company history timeline
Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer.
Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard.
Willard H. Dere, M.D., joined the University of Utah Health Sciences Center in November 2014 as the Executive Director of Personalized Health and Professor of Internal Medicine.
14, 2017, to develop microbiome therapies to improve the outcomes for cancer patients.
Arkowitz served as the Chief Financial Officer of Flexion Therapeutics, a biotechnology company, since 2018 and has responsibility for the finance and accounting, corporate communications and investor relations, information technology, and Chemistry, Manufacturing and Controls (CMC) functions.
Following the acquisition of GSK in January 2019, Kristin led all integration communications efforts leading to improved employee retention and engagement.
Paul Biondi serves as Executive Partner and President of Pioneering Medicines at Flagship Pioneering where he has been since November 2019.
SER-109 co-commercialization agreement for North America with Nestlé Health Science announced July 1, 2021.
Rate how well Seres Therapeutics lives up to its initial vision.
Seres Therapeutics jobs
Do you work at Seres Therapeutics?
Does Seres Therapeutics communicate its history to new hires?
Seres Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Applied Molecular Transport | 2015 | $8.3M | 80 | - |
| PTC Therapeutics | 1998 | $806.8M | 517 | 13 |
| Cara Therapeutics | 2004 | $7.1M | 84 | - |
| Anacor Pharmaceutical | 2000 | $82.4M | 100 | - |
| Onconova Therapeutics | 1998 | $226,000 | 12 | - |
| Synthetic Biologics | 2001 | $2.6M | 13 | - |
| Omeros | 1994 | $29.9M | 265 | 1 |
| Sorbent Therapeutics | 2005 | - | 31 | - |
| Allakos | 2012 | $15.6M | 125 | 14 |
| Gossamer Bio | 2015 | $114.7M | 100 | 11 |
Seres Therapeutics history FAQs
Zippia gives an in-depth look into the details of Seres Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Seres Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Seres Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Seres Therapeutics. The data presented on this page does not represent the view of Seres Therapeutics and its employees or that of Zippia.
Seres Therapeutics may also be known as or be related to SERES THERAPEUTICS INC., Seres Therapeutics, Seres Therapeutics Inc and Seres Therapeutics, Inc.